Fortress Biotech (FBIO) Set to Release Quarterly Earnings on Monday

Fortress Biotech (NASDAQ:FBIO) is expected to post its Q3 2026 results before the market opens on Monday, November 16th. Analysts expect the company to post earnings of ($0.27) per share and revenue of $21.57 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Fortress Biotech (NASDAQ:FBIO) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.12. Fortress Biotech had a return on equity of 83.47% and a net margin of 163.32%. The company had revenue of $18.72 million for the quarter, compared to analyst estimates of $18.30 million.

Fortress Biotech Stock Performance

Shares of FBIO opened at $1.85 on Monday. Fortress Biotech has a 52-week low of $1.79 and a 52-week high of $4.53. The business’s fifty day moving average is $2.21 and its 200-day moving average is $2.76. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.83 and a current ratio of 3.96. The firm has a market cap of $61.70 million, a price-to-earnings ratio of 0.70 and a beta of 1.27.

Wall Street Analyst Weigh In

FBIO has been the subject of several recent analyst reports. Wall Street Zen downgraded Fortress Biotech from a “strong-buy” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings lowered Fortress Biotech from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 23rd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $17.00.

Fortress Biotech Company Profile

Fortress Biotech, Inc (NASDAQ: FBIO) is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiary companies and strategic partnerships. Its research and development activities have focused on areas including dermatology, immunology, oncology, rare diseases and other conditions with significant unmet medical needs.

The company’s portfolio has included dermatology products such as ZILXI, a topical minocycline foam for the treatment of inflammatory lesions associated with rosacea, and Qbrexza, a topical treatment for primary axillary hyperhidrosis.